FDA approves Takeda's Brintellix for depression

Drug to be available in four strengths

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug developed by Takeda to treat major depressive disorder, the agency said.

The FDA announced the approval of Brintellix (vortioxetine) tablets for treating MDD in adults. The drug will be available in the 5-mg, 10-mg, 15-mg and 20-mg strengths.

"Major depressive disorder can be disabling and can keep a person from functioning normally," FDA Division of Psychiatry Products acting director Mitchell Mathis said. "Since medications affect everyone differently, it is important to have a variety of treatment options available for patients who suffer from depression."


Login or Register to post a comment.